Stenting of the unprotected left main coronary artery in patients with severe aortic stenosis prior to percutaneous valve interventions |
| |
Authors: | Ronen Jaffe Ariel Finkelstein Basil S. Lewis Victor Guetta Nader Khader Ronen Rubinshtein David A. Halon Amit Segev |
| |
Affiliation: | 1. Interventional Cardiology, San Raffaele Scientific Institute, Milan, Italy;2. Institution of Cardiovascular Research, Xinqiao Hospital, Third Military Medical University, Chongqing, China;1. Fondazione C.N.R. G. Monasterio, Ospedale del Cuore, Via Aurelia Sud, 54100 Massa, MS, Italy;2. Clinical and Interventional Cardiology, Sassari University Hospital, Via Enrico de Nicola, 07100 Sassari, SS, Italy |
| |
Abstract: | AimsHigh-risk patients with severe aortic stenosis (AS) who are candidates for transcatheter valve implantation (TAVI) or balloon aortic valvuloplasty (BAV) may additionally require revascularization of the unprotected left main coronary artery (UPLM). We aimed to assess the feasibility and procedural safety of UPLM stenting in such patients.Methods and ResultsTen cases of UPLM stenting prior to BAV or TAVI at three medical centers over a 2-year period were identified. Mean age was 84±4 years, aortic valve area was 0.70±0.12 cm2, left ventricular ejection fraction was 58%±3%, and logistic EuroScore was 32±17. Intraaortic balloon counterpulsation was used in three patients. A single stent was used in seven patients, and two stents were used in three patients. One patient received a bare-metal stent, and the others received drug-eluting stents. No procedural complications occurred, and the patients were hemodynamically stable. Three patients subsequently underwent BAV, and seven underwent TAVI. During 6 months of follow-up, two patients died: one due to AS restenosis 6 months after BAV and one due to vascular complications 18 days after TAVI (34 days after UPLM stenting).ConclusionsStenting of the UPLM in patients with severe AS prior to percutaneous valve intervention seems feasible and safe. This approach may enable more patients to achieve comprehensive percutaneous therapy for severe coronary and valvular disease. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|